Experimental drug for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug (RJK-RT2831) for people with AML that has not responded to standard treatments. The drug targets two markers on leukemia cells (CD33 and CD123). The study is early-stage, aiming to find the right dose and check safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 74 years old with acute myeloid leukemia (AML) that has come back or not responded to prior treatment.
- Your leukemia cells must test positive for a protein called CD33 or CD123 (any level of positivity is okay).
- You need to be in reasonably good health with normal liver, kidney, and heart function, and an ECOG performance status of 0 to 2 (able to do most daily activities).
- You cannot have received certain anti-cancer treatments (like chemotherapy, targeted therapy, or immunotherapy) within 14 days before starting the study drug, or have had a stem cell transplant or CAR-T therapy within a specified time frame.
- You must not have had prior treatment with drugs that target CD33 (like Mylotarg) or CD123 (like Elzonris).
- You must agree to use effective birth control if you are able to have children, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This early-phase trial tests an 'off-the-shelf' immune cell treatment (CAR-NK cells) that targets a protein called CD123 on leukemia cells. It's for people with AML that has returned or hasn't responded to standard treatments.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.